company background image
ALT

Altimmune NasdaqGM:ALT Stock Report

Last Price

US$5.02

Market Cap

US$215.4m

7D

-2.7%

1Y

-64.2%

Updated

21 May, 2022

Data

Company Financials +
ALT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ALT Stock Overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

Altimmune Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Altimmune
Historical stock prices
Current Share PriceUS$5.02
52 Week HighUS$19.46
52 Week LowUS$3.83
Beta1.44
1 Month Change10.33%
3 Month Change-28.90%
1 Year Change-64.17%
3 Year Change100.00%
5 Year Change-96.23%
Change since IPO-97.89%

Recent News & Updates

Apr 07

Altimmune's New Avatar As A Liver Disease Player

Altimmune used to be an infectious disease player. After a lot of upheavals last year, it has now moved on to obesity, NASH and NAFLD. I am curious to see how this evolves.

Shareholder Returns

ALTUS BiotechsUS Market
7D-2.7%1.4%-2.7%
1Y-64.2%-21.7%-12.9%

Return vs Industry: ALT underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: ALT underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is ALT's price volatile compared to industry and market?
ALT volatility
ALT Average Weekly Movement12.0%
Biotechs Industry Average Movement12.3%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: ALT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ALT's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199747Vipin Garghttps://altimmune.com

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

Altimmune Fundamentals Summary

How do Altimmune's earnings and revenue compare to its market cap?
ALT fundamental statistics
Market CapUS$215.43m
Earnings (TTM)-US$101.66m
Revenue (TTM)US$3.60m

59.8x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALT income statement (TTM)
RevenueUS$3.60m
Cost of RevenueUS$79.73m
Gross Profit-US$76.12m
Other ExpensesUS$25.53m
Earnings-US$101.66m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.37
Gross Margin-2,111.97%
Net Profit Margin-2,820.39%
Debt/Equity Ratio0%

How did ALT perform over the long term?

See historical performance and comparison

Valuation

Is Altimmune undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.17x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ALT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ALT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALT is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (1.5x).


Future Growth

How is Altimmune forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-13.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALT's revenue (86.4% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: ALT's revenue (86.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Altimmune performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-22.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALT is currently unprofitable.

Growing Profit Margin: ALT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALT is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.

Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: ALT has a negative Return on Equity (-54.99%), as it is currently unprofitable.


Financial Health

How is Altimmune's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALT's short term assets ($191.1M) exceed its short term liabilities ($19.1M).

Long Term Liabilities: ALT's short term assets ($191.1M) exceed its long term liabilities ($1.7M).


Debt to Equity History and Analysis

Debt Level: ALT is debt free.

Reducing Debt: ALT has no debt compared to 5 years ago when its debt to equity ratio was 14.5%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALT has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 45% each year.


Dividend

What is Altimmune current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Vipin Garg (63 yo)

3.5yrs

Tenure

US$2,631,639

Compensation

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...


CEO Compensation Analysis

Compensation vs Market: Vipin's total compensation ($USD2.63M) is above average for companies of similar size in the US market ($USD1.68M).

Compensation vs Earnings: Vipin's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ALT's management team is considered experienced (3.7 years average tenure).


Board Members

Experienced Board: ALT's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.2%.


Top Shareholders

Company Information

Altimmune, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Altimmune, Inc.
  • Ticker: ALT
  • Exchange: NasdaqGM
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$215.425m
  • Shares outstanding: 42.91m
  • Website: https://altimmune.com

Number of Employees


Location

  • Altimmune, Inc.
  • 910 Clopper Road
  • Suite 201S
  • Gaithersburg
  • Maryland
  • 20878
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.